39 results
Amyvid (florbetapir f 18)
(Florbetapir F 18)Eli Lilly and Company
Usage: Amyvid is indicated for PET imaging to assess β-amyloid plaque density in adults with cognitive impairment being evaluated for Alzheimer's Disease (AD) and other cognitive decline causes. It serves as an adjunct to other diagnostic assessments but does not confirm a diagnosis or predict dementia development.
Bamlanivimab (bamlanivimab)
(Bamlanivimab)Eli Lilly and Company
Baqsimi (glucagon)
(glucagon)Eli Lilly and Company
Usage: BAQSIMI™ is indicated for treating severe hypoglycemia in adults and pediatric patients with diabetes aged 4 years and older.
Baricitinib (baricitinib)
(baricitinib)Eli Lilly and Company
Basaglar (insulin glargine)
(Insulin glargine)Eli Lilly and Company
Usage: BASAGLAR® is indicated for improving glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. It is not recommended for treating diabetic ketoacidosis.
Bebtelovimab (bebtelovimab)
(Bebtelovimab)Eli Lilly and Company
Cialis (tadalafil)
(Tadalafil)Eli Lilly and Company
Usage: CIALIS® is indicated for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and both conditions simultaneously (ED/BPH). If used with finasteride for BPH, treatment is recommended for up to 26 weeks due to diminishing benefits thereafter.
Cymbalta (duloxetine hydrochloride)
(Duloxetine hydrochloride)Eli Lilly and Company
Usage: CYMBALTA® is indicated for the treatment of major depressive disorder, generalized anxiety disorder (in adults and children 7+), diabetic peripheral neuropathic pain, fibromyalgia (in adults and those 13+), and chronic musculoskeletal pain in adults.
Cyramza (ramucirumab)
(ramucirumab)Eli Lilly and Company
Usage: CYRAMZA is indicated for treating adults with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and hepatocellular carcinoma. It is used alone or in combination with specific chemotherapy agents, depending on disease progression and specific tumor characteristics.
Ebglyss (lebrikizumab-lbkz)
(lebrikizumab-lbkz)Eli Lilly and Company
Usage: EBGLYSS is indicated for treating moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and older, weighing at least 40 kg, whose condition is insufficiently controlled by topical therapies or when those therapies are not suitable. It may be used with or without topical corticosteroids.